X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs GLENMARK PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS GLENMARK PHARMA NOVARTIS/
GLENMARK PHARMA
 
P/E (TTM) x 351.0 14.1 2,482.9% View Chart
P/BV x 17.3 4.0 436.4% View Chart
Dividend Yield % 1.7 0.3 520.6%  

Financials

 NOVARTIS   GLENMARK PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-16
GLENMARK PHARMA
Mar-16
NOVARTIS/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs9821,262 77.8%   
Low Rs556672 82.8%   
Sales per share (Unadj.) Rs252.9270.6 93.5%  
Earnings per share (Unadj.) Rs62.124.9 249.8%  
Cash flow per share (Unadj.) Rs63.334.4 183.9%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.30.2 628.5%  
Book value per share (Unadj.) Rs363.6151.3 240.3%  
Shares outstanding (eoy) m31.96282.16 11.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.03.6 85.1%   
Avg P/E ratio x12.438.9 31.8%  
P/CF ratio (eoy) x12.228.1 43.3%  
Price / Book Value ratio x2.16.4 33.1%  
Dividend payout %16.18.0 200.2%   
Avg Mkt Cap Rs m24,580272,778 9.0%   
No. of employees `0000.810.0 7.5%   
Total wages/salary Rs m1,80113,782 13.1%   
Avg. sales/employee Rs Th10,748.97,614.9 141.2%   
Avg. wages/employee Rs Th2,395.21,374.8 174.2%   
Avg. net profit/employee Rs Th2,641.1700.2 377.2%   
INCOME DATA
Net Sales Rs m8,08376,340 10.6%  
Other income Rs m829356 232.8%   
Total revenues Rs m8,91376,696 11.6%   
Gross profit Rs m23414,172 1.7%  
Depreciation Rs m372,691 1.4%   
Interest Rs m21,789 0.1%   
Profit before tax Rs m1,02510,048 10.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m7523,028 24.8%   
Profit after tax Rs m1,9867,019 28.3%  
Gross profit margin %2.918.6 15.6%  
Effective tax rate %73.430.1 243.4%   
Net profit margin %24.69.2 267.2%  
BALANCE SHEET DATA
Current assets Rs m12,67859,096 21.5%   
Current liabilities Rs m2,43340,018 6.1%   
Net working cap to sales %126.725.0 507.1%  
Current ratio x5.21.5 352.9%  
Inventory Days Days3375 43.6%  
Debtors Days Days22119 18.9%  
Net fixed assets Rs m6939,075 0.2%   
Share capital Rs m160282 56.6%   
"Free" reserves Rs m11,46030,281 37.8%   
Net worth Rs m11,62142,703 27.2%   
Long term debt Rs m024,873 0.0%   
Total assets Rs m14,400111,026 13.0%  
Interest coverage x570.56.6 8,622.3%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.60.7 81.6%   
Return on assets %13.87.9 174.0%  
Return on equity %17.116.4 104.0%  
Return on capital %23.617.5 134.6%  
Exports to sales %0.743.3 1.7%   
Imports to sales %18.67.4 250.2%   
Exports (fob) Rs m6033,044 0.2%   
Imports (cif) Rs m1,5035,672 26.5%   
Fx inflow Rs m18636,945 0.5%   
Fx outflow Rs m1,82161,066 3.0%   
Net fx Rs m-1,635-24,122 6.8%   
CASH FLOW
From Operations Rs m2,5313,449 73.4%  
From Investments Rs m-8,270-8,802 94.0%  
From Financial Activity Rs m-3866,986 -5.5%  
Net Cashflow Rs m-6,125934 -655.9%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 6.9 29.0%  
FIIs % 1.6 34.4 4.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 10.5 204.8%  
Shareholders   41,647 56,727 73.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   CIPLA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 16, 2017 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - STERLING BIOTECH COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS